Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry

Rationale: Two antifibrotic medications, nintedanib and pirfenidone, have been approved for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States. Few data have been published on the use of these medications in clinical practice. Objectives: To investigate patterns of use of anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Salisbury, Margaret L., Conoscenti, Craig S., Culver, Daniel A., Yow, Eric, Neely, Megan L., Bender, Shaun, Hartmann, Nadine, Palmer, Scott M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640723/
https://www.ncbi.nlm.nih.gov/pubmed/32574517
http://dx.doi.org/10.1513/AnnalsATS.201912-880OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640723/
https://www.ncbi.nlm.nih.gov/pubmed/32574517
http://dx.doi.org/10.1513/AnnalsATS.201912-880OC

Ejemplares similares